Target
Nuclear receptor ROR-alpha
Ligand
BDBM382357
Substrate
n/a
Meas. Tech.
ChEMBL_1837937 (CHEMBL4338070)
IC50
>10000±n/a nM
Citation
 Marcoux, DDuan, JJShi, QCherney, RJSrivastava, ASCornelius, LBatt, DGLiu, QBeaudoin-Bertrand, MWeigelt, CAKhandelwal, PVishwakrishnan, SSelvakumar, KKarmakar, AGupta, AKBasha, MRamlingam, SManjunath, NVanteru, SKarmakar, SMaddala, NVetrichelvan, MGupta, ARampulla, RAMathur, AYip, SLi, PWu, DRKhan, JRuzanov, MSack, JSWang, JYarde, MCvijic, MELi, SShuster, DJBorowski, VXie, JHMcIntyre, KWObermeier, MTFura, AStefanski, KCornelius, GHynes, JTino, JAMacor, JESalter-Cid, LDenton, RZhao, QCarter, PHDhar, TGM Rationally Designed, Conformationally Constrained Inverse Agonists of ROR?t-Identification of a Potent, Selective Series with Biologic-Like in Vivo Efficacy. J Med Chem 62:9931-9946 (2019) [PubMed]  Article 
Target
Name:
Nuclear receptor ROR-alpha
Synonyms:
NR1F1 | Nuclear receptor RZR-alpha | Nuclear receptor subfamily 1 group F member 1 | RAR-related orphan receptor A | RORA | RORA_HUMAN | RZRA | Retinoid-related orphan receptor-alpha
Type:
PROTEIN
Mol. Mass.:
58976.26
Organism:
Homo sapiens (Human)
Description:
ChEMBL_101591
Residue:
523
Sequence:
MESAPAAPDPAASEPGSSGADAAAGSRETPLNQESARKSEPPAPVRRQSYSSTSRGISVTKKTHTSQIEIIPCKICGDKSSGIHYGVITCEGCKGFFRRSQQSNATYSCPRQKNCLIDRTSRNRCQHCRLQKCLAVGMSRDAVKFGRMSKKQRDSLYAEVQKHRMQQQQRDHQQQPGEAEPLTPTYNISANGLTELHDDLSNYIDGHTPEGSKADSAVSSFYLDIQPSPDQSGLDINGIKPEPICDYTPASGFFPYCSFTNGETSPTVSMAELEHLAQNISKSHLETCQYLREELQQITWQTFLQEEIENYQNKQREVMWQLCAIKITEAIQYVVEFAKRIDGFMELCQNDQIVLLKAGSLEVVFIRMCRAFDSQNNTVYFDGKYASPDVFKSLGCEDFISFVFEFGKSLCSMHLTEDEIALFSAFVLMSADRSWLQEKVKIEKLQQKIQLALQHVLQKNHREDGILTKLICKVSTLRALCGRHTEKLMAFKAIYPDIVRLHFPPLYKELFTSEFEPAMQIDG
  
Inhibitor
Name:
BDBM382357
Synonyms:
US10273259, Example 70 | US10711020, Example 70
Type:
Small organic molecule
Emp. Form.:
C29H27F8NO6S
Mol. Mass.:
669.58
SMILES:
OC(=O)[C@H]1CC[C@@](O)(CC1)C(=O)N1CC[C@@]2([C@H]1CCc1cc(ccc21)C(F)(C(F)(F)F)C(F)(F)F)S(=O)(=O)c1ccc(F)cc1 |r,wU:16.17,3.2,6.6,wD:6.10,15.38,(-6.97,3.38,;-7.73,2.04,;-9.27,2.04,;-6.96,.71,;-5.42,.72,;-4.64,-.61,;-5.41,-1.95,;-5.67,-3.47,;-6.95,-1.95,;-7.72,-.62,;-3.96,-2.47,;-3.69,-3.98,;-2.78,-1.47,;-2.9,.06,;-1.47,.64,;-.48,-.53,;-1.29,-1.84,;-.56,-3.2,;.98,-3.25,;1.79,-1.94,;3.33,-1.99,;4.14,-.68,;3.41,.68,;1.87,.73,;1.06,-.58,;5.68,-.73,;5.73,.81,;7.22,-.77,;8.76,-.82,;7.17,-2.31,;7.27,.77,;5.63,-2.26,;4.28,-2.99,;6.94,-3.08,;5.58,-3.8,;.19,.85,;1.66,1.33,;.51,2.36,;-.67,2.13,;-2.21,2.01,;-3.07,3.29,;-2.4,4.67,;-3.27,5.95,;-.87,4.79,;-0,3.51,)|
Structure:
Search PDB for entries with ligand similarity: